Neumora Therapeutics Inc.... (NMRA)
1.94
-0.07 (-3.48%)
At close: Jan 29, 2025, 3:59 PM
1.93
-0.26%
After-hours Jan 29, 2025, 07:15 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 |
| Net Income | -235.93M | -130.90M | -237.31M | -99.27M |
| Depreciation & Amortization | 668.00K | 594.00K | 538.00K | 105.00K |
| Stock-Based Compensation | 17.24M | 8.30M | 4.27M | 1.68M |
| Other Working Capital | -8.32M | -5.70M | -202.00K | 1.55M |
| Other Non-Cash Items | 63.64M | 15.35M | 158.09M | 70.77M |
| Deferred Income Tax | n/a | -1.28M | -53.00K | 3.08M |
| Change in Working Capital | -8.90M | -6.95M | -961.00K | -3.12M |
| Operating Cash Flow | -163.28M | -114.90M | -75.42M | -26.76M |
| Capital Expenditures | -117.00K | -511.00K | -817.00K | -1.30M |
| Acquisitions | n/a | n/a | n/a | n/a |
| Purchase of Investments | -109.07M | -226.37M | n/a | n/a |
| Sales Maturities Of Investments | 178.17M | 71.87M | n/a | n/a |
| Other Investing Acitivies | -4.59M | -13.00M | n/a | -9.94M |
| Investing Cash Flow | 64.39M | -168.01M | -817.00K | -11.24M |
| Debt Repayment | n/a | n/a | n/a | 55.91M |
| Common Stock Repurchased | -491.00K | n/a | n/a | -2.00K |
| Dividend Paid | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | -948.00K | 115.74M | 292.55M | 171.01M |
| Financial Cash Flow | 231.94M | 115.74M | 293.51M | 230.10M |
| Net Cash Flow | 133.04M | -167.17M | 217.27M | 192.10M |
| Free Cash Flow | -163.40M | -115.41M | -76.24M | -28.06M |